{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:30:08Z","timestamp":1778509808571,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T00:00:00Z","timestamp":1469145600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00520-016-3313-0","type":"journal-article","created":{"date-parts":[[2016,7,21]],"date-time":"2016-07-21T21:12:15Z","timestamp":1469135535000},"page":"277-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["2016 Updated MASCC\/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy"],"prefix":"10.1007","volume":"25","author":[{"given":"J\u00f8rn","family":"Herrstedt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Roila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Warr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Celio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolph M.","family":"Navari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Hesketh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matti S.","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,22]]},"reference":[{"issue":"Suppl 1","key":"3313_CR1","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1007\/s00520-010-0976-9","volume":"19","author":"MG Kris","year":"2011","unstructured":"Kris MG, Tonato M, Bria E, Ballatori E, Espersen B, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Saito M, Morrow G, Hesketh P (2011) Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 19(Suppl 1):S25\u2013S32","journal-title":"Support Care Cancer"},{"issue":"Suppl","key":"3313_CR2","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/s00520-010-0951-5","volume":"19","author":"J Herrstedt","year":"2011","unstructured":"Herrstedt J, Rapoport B, Warr D, Roila F, Bria E, Rittenberg C, Hesketh PJ (2011) Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer 19(Suppl):S15\u2013S23","journal-title":"Support Care Cancer"},{"issue":"suppl 5","key":"3313_CR3","doi-asserted-by":"crossref","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","volume":"21","author":"F Roila","year":"2010","unstructured":"Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(suppl 5):v232\u2013v243","journal-title":"Ann Oncol"},{"key":"3313_CR4","doi-asserted-by":"crossref","unstructured":"Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Warr D, Hesketh PJ (2016) Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer 24 (in review)","DOI":"10.1007\/s00520-016-3332-x"},{"key":"3313_CR5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(09)70109-3","volume":"10","author":"SM Grunberg","year":"2009","unstructured":"Grunberg SM, Rolski J, Strausz J, Aziz Z, Lane S, Russo MW, Wissel P, Guckert M, Wright O, Herrstedt J (2009) Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:549\u2013558","journal-title":"Lancet Oncol"},{"key":"3313_CR6","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.2009.21.8511","volume":"27","author":"J Herrstedt","year":"2009","unstructured":"Herrstedt J, Apornwirat W, Shaharyar A, Aziz Z, Roila F, Van Belle S, Russo MW, Levin J, Ranganathan S, Guckert M, Grunberg SM (2009) Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 27:5363\u20135369","journal-title":"J Clin Oncol"},{"key":"3313_CR7","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1517\/14740338.2014.954546","volume":"13","author":"L Brygger","year":"2014","unstructured":"Brygger L, Herrstedt J (2014) 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects. Expert Opin Drug Saf 13:1407\u20131422","journal-title":"Expert Opin Drug Saf"},{"key":"3313_CR8","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00520-010-0990-y","volume":"19","author":"RV Boccia","year":"2011","unstructured":"Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM, Sancuso Study Group (2011) Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 19:1609\u20131617","journal-title":"Support Care Cancer"},{"key":"3313_CR9","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1007\/s00520-015-2657-1","volume":"23","author":"M Karthaus","year":"2015","unstructured":"Karthaus M, Tibor C, Lorusso V et al (2015) Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC). Support Care Cancer 23:2917\u20132923","journal-title":"Support Care Cancer"},{"key":"3313_CR10","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00520-012-1691-5","volume":"21","author":"R Boccia","year":"2013","unstructured":"Boccia R, Grunberg S, Franco-Gonzales E, Rubenstein E, Voisin D (2013) Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial. Support Care Cancer 21:1453\u20131460","journal-title":"Support Care Cancer"},{"key":"3313_CR11","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1200\/JCO.2010.31.7859","volume":"29","author":"S Grunberg","year":"2011","unstructured":"Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol\u2014EASE. J Clin Oncol 29:1495\u20131501","journal-title":"J Clin Oncol"},{"key":"3313_CR12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/clpt.2012.62","volume":"92","author":"K Laere Van","year":"2012","unstructured":"Van Laere K, De Hoon J, Bormans G, Koole M, Derdelinckx I, De Lepeleire I, Declercq R, Sanabria Bohorquez SM, Hamill T, Mozley PD, Tatosian D, Xie W, Liu Y, Liu F, Zappacosta P, Mahon C, Butterfield KL, Rosen LB, Murphy MG, Hargreaves RJ, Wagner JA, Shadle CR (2012) Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. Clin Pharmacol Ther 92:243\u2013250","journal-title":"Clin Pharmacol Ther"},{"key":"3313_CR13","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","volume":"25","author":"PJ Hesketh","year":"2014","unstructured":"Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla RJ (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340\u20131346","journal-title":"Ann Oncol"},{"key":"3313_CR14","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1007\/s00520-015-2738-1","volume":"23","author":"B Rapoport","year":"2015","unstructured":"Rapoport B, Chua D, Poma A et al (2015) Study of rolapitant, a novel, long-acting, NK1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting due to highly emetogenic chemotherapy. Support Care Cancer 23:3281\u20133288","journal-title":"Support Care Cancer"},{"key":"3313_CR15","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1200\/JCO.1998.16.9.2937","volume":"16","author":"The Italian group for Antiemetic Research","year":"1998","unstructured":"The Italian group for Antiemetic Research (1998) Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 16:2937\u20132942","journal-title":"J Clin Oncol"},{"key":"3313_CR16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1200\/JCO.2004.09.040","volume":"22","author":"The Italian group for Antiemetic Research","year":"2004","unstructured":"The Italian group for Antiemetic Research (2004) Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 22:725\u2013729","journal-title":"J Clin Oncol"},{"key":"3313_CR17","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00520-010-0941-7","volume":"19","author":"L Celio","year":"2011","unstructured":"Celio L, Frustaci S, Denaro A et al (2011) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomised, multicenter, phase III trial. Support Care Cancer 19:1217\u20131225","journal-title":"Support Care Cancer"},{"key":"3313_CR18","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/annonc\/mdp584","volume":"21","author":"M Aapro","year":"2010","unstructured":"Aapro M, Fabi A, Nole F et al (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083\u20131088","journal-title":"Ann Oncol"},{"key":"3313_CR19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00520-012-1558-9","volume":"21","author":"L Celio","year":"2013","unstructured":"Celio L, Bonizzoni E, Bajetta E, Sebastiani S, Perrone T, Aapro MS (2013) Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline\/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials. Support Care Cancer 21:565\u2013573","journal-title":"Support Care Cancer"},{"key":"3313_CR20","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00520-014-2400-3","volume":"23","author":"H Raftopoulos","year":"2015","unstructured":"Raftopoulos H, Cooper W, O\u2019Boyle E, Gabrail N, Boccia R, Gralla RJ (2015) Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Support Care Cancer 23:723\u2013732","journal-title":"Support Care Cancer"},{"key":"3313_CR21","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1200\/JCO.2011.39.8123","volume":"30","author":"JA Roscoe","year":"2012","unstructured":"Roscoe JA, Heckler CE, Morrow GR et al (2012) Prevention of delayed nausea: a University Of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. J Clin Oncol 30:3389\u20133395","journal-title":"J Clin Oncol"},{"key":"3313_CR22","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112\u20134119","journal-title":"J Clin Oncol"},{"key":"3313_CR23","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.11433","volume":"97","author":"S Poli-Bigelli","year":"2003","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090\u20133098","journal-title":"Cancer"},{"key":"3313_CR24","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/annonc\/mdl019","volume":"17","author":"HJ Schmoll","year":"2006","unstructured":"Schmoll HJ, Aapro MS, Poli-Bigelli S et al (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17:1000\u20131006","journal-title":"Ann Oncol"},{"key":"3313_CR25","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mds541","volume":"24","author":"H Saito","year":"2013","unstructured":"Saito H, Yoshizawa H, Yoshimori K, Katakami N, Katsumata N, Kawahara M, Eguchi K (2013) Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol 24:1067\u20131073","journal-title":"Ann Oncol"},{"key":"3313_CR26","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00520-013-2043-9","volume":"22","author":"Z Hu","year":"2014","unstructured":"Hu Z, Cheng Y, Zhang H, Zhou C, Han B, Zhang Y et al (2014) Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial. Support Care Cancer 22:979\u2013987","journal-title":"Support Care Cancer"},{"key":"3313_CR27","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","volume":"23","author":"DG Warr","year":"2005","unstructured":"Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822\u20132830","journal-title":"J Clin Oncol"},{"key":"3313_CR28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00520-009-0680-9","volume":"18","author":"BL Rapoport","year":"2010","unstructured":"Rapoport BL, Jordan K, Boice JA et al (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423\u2013431","journal-title":"Support Care Cancer"},{"key":"3313_CR29","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","volume":"25","author":"RJ Gralla","year":"2014","unstructured":"Gralla RJ, Bosnjak SM, Hontsa A, Balser C, Rizzi G, Rossi G, Borroni ME, Jordan K (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25:1333\u20131339","journal-title":"Ann Oncol"},{"key":"3313_CR30","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","volume":"25","author":"M Aapro","year":"2014","unstructured":"Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwarcbrszberg L, Grunberg S (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328\u20131333","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"3313_CR31","first-page":"636","volume":"32","author":"B Rapoport","year":"2014","unstructured":"Rapoport B, Poma A, Hedley ML, Martell RE, Navari RM (2014) Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting in subjects receiving highly emetogenic chemotherapy. J Clin Oncol 32(suppl 5):636, A 9638","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"3313_CR32","first-page":"635","volume":"32","author":"ID Schnadig","year":"2014","unstructured":"Schnadig ID, Modiano MR, Poma A, Hedley ML, Martell RE, Schwartzberg LS (2014) Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol 32(suppl 5):635, A9633","journal-title":"J Clin Oncol"},{"key":"3313_CR33","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1470-2045(15)00035-2","volume":"16","author":"BL Rapoport","year":"2015","unstructured":"Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 16:1079\u20131089","journal-title":"Lancet Oncol"},{"key":"3313_CR34","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1470-2045(15)00034-0","volume":"16","author":"LS Schwartzberg","year":"2015","unstructured":"Schwartzberg LS, Modiano MR, Rapoport BL, Chasen MR, Gridelli C, Urban L, Poma A, Arora S, Navari RM, Schnadig ID (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol 16:1071\u20131078","journal-title":"Lancet Oncol"},{"key":"3313_CR35","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1124\/dmd.104.000216","volume":"32","author":"RI Sanchez","year":"2004","unstructured":"Sanchez RI, Wang RW, Newton DJ, Bakhtiar R, Lu P, Chiu S-H, Evans DC, Huskey SE (2004) Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist, aprepitant. Drug Metab Dis 32:1287\u20131292","journal-title":"Drug Metab Dis"},{"key":"3313_CR36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0009-9236(03)00123-1","volume":"74","author":"AK Majumdar","year":"2003","unstructured":"Majumdar AK, McCrea JB, Panebianco DL et al (2003) Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 74:150\u2013156","journal-title":"Clin Pharmacol Ther"},{"key":"3313_CR37","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1007\/s00520-013-1857-9","volume":"21","author":"S Calcagnile","year":"2013","unstructured":"Calcagnile S, Lanzarotti C, Rossi G et al (2013) Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer 21:2879\u20132887","journal-title":"Support Care Cancer"},{"key":"3313_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215586824","author":"JJ Natale","year":"2015","unstructured":"Natale JJ, Spinelli T, Calcagnile S, Lanzarotti C, Rossi G, Cox D, Kashef K (2015) Drug\u2013drug interaction profile of components of a fixed combination of netupitant and palonosetron: review of clinical data. J Oncol Pharm Pract. doi: 10.1177\/1078155215586824","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"3313_CR39","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ctrv.2015.09.005","volume":"41","author":"C Rojas","year":"2015","unstructured":"Rojas C, Slusher BS (2015) Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: rolapitant and NEPA (netupitant\/palonosetron). Cancer Treat Rev 41(10):904\u2013913","journal-title":"Cancer Treat Rev"},{"key":"3313_CR40","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1124\/dmd.104.000216","volume":"32","author":"RI Sanchez","year":"2004","unstructured":"Sanchez RI, Wang RW, Newton DJ et al (2004) Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 32:1287\u20131292","journal-title":"Drug Metab Dispos"},{"key":"3313_CR41","unstructured":"Einhorn LH, Rapoport B, Navari R, Herrstedt J, Brames MJ (2016). Antiemetic therapy for multiple-day chemotherapy, high dose chemotherapy, and breakthrough nausea and vomiting: review and consensus statements. Support Care Cancer 24."},{"key":"3313_CR42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1756-9966-28-131","volume":"28","author":"L Tan","year":"2009","unstructured":"Tan L, Liu J, Liu X et al (2009) Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:131. doi: 10.1186\/1756-9966-28-131","journal-title":"J Exp Clin Cancer Res"},{"key":"3313_CR43","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188\u2013195","journal-title":"J Support Oncol"},{"key":"3313_CR44","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jpainsymman.2013.05.003","volume":"47","author":"N Mizukami","year":"2014","unstructured":"Mizukami N, Yamanchi M, Koike K et al (2014) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manag 47:542\u2013550","journal-title":"J Pain Symptom Manag"},{"key":"3313_CR45","unstructured":"Navari RM, Nagy CK (2015). Olanzapine versus fosaprepitant for the prevention of nausea and vomiting in patients receiving concurrent chemoradiation treatment. J Clin Oncol 33: (suppl; abstr 9502)."},{"key":"3313_CR46","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00520-015-2829-z","volume":"24","author":"M Abe","year":"2016","unstructured":"Abe M, Hirashima Y, Kasamatsu Y et al (2016) Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Support Care Cancer 24:675\u2013682","journal-title":"Support Care Cancer"},{"issue":"suppl 29S","key":"3313_CR47","doi-asserted-by":"crossref","first-page":"abstract 176","DOI":"10.1200\/jco.2015.33.29_suppl.176","volume":"33","author":"RM Navari","year":"2015","unstructured":"Navari RM, Qin R, Ruddy KJ et al (2015) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): alliance A221301, a randomized, double-blind, placebo-controlled trial. J Clin Oncol 33(suppl 29S):abstract 176","journal-title":"J Clin Oncol"},{"key":"3313_CR48","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/annonc\/mdv132","volume":"26","author":"F Roila","year":"2015","unstructured":"Roila F, Ruggeri B, Ballatori E et al (2015) Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Ann Oncol 26:1248\u20131253","journal-title":"Ann Oncol"},{"key":"3313_CR49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/JCO.2013.51.4547","volume":"32","author":"F Roila","year":"2013","unstructured":"Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M (2013) Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol 32:101\u2013106","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3313-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-016-3313-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3313-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T11:48:43Z","timestamp":1568202523000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-016-3313-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,22]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["3313"],"URL":"https:\/\/doi.org\/10.1007\/s00520-016-3313-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,22]]}}}